PE20210042A1 - Metodos para detectar transtiretina - Google Patents
Metodos para detectar transtiretinaInfo
- Publication number
- PE20210042A1 PE20210042A1 PE2020000647A PE2020000647A PE20210042A1 PE 20210042 A1 PE20210042 A1 PE 20210042A1 PE 2020000647 A PE2020000647 A PE 2020000647A PE 2020000647 A PE2020000647 A PE 2020000647A PE 20210042 A1 PE20210042 A1 PE 20210042A1
- Authority
- PE
- Peru
- Prior art keywords
- ttr
- antibody
- misfolded
- biological sample
- transthyretin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/66—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/30—Electrochemically active labels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Plasma & Fusion (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
Se refiere a un metodo para detectar transtiretina (TTR) mal plegada en una muestra biologica, comprendiendo el metodo: (a) poner en contacto una muestra biologica con un anticuerpo de captura que se une especificamente a un epitope dentro de los residuos 89-97 de TTR y un anticuerpo reportero que se une especificamente a un epitope diferente de TTR; en donde si esta presente TTR mal plegada en la muestra, el anticuerpo de captura y el anticuerpo reportero se unen a la TTR mal plegada formando un complejo sandwich; y (b) detectar el anticuerpo reportero que forma un complejo sandwich en la etapa (a), para indicar la presencia o ausencia de la TTR mal plegada. La muestra biologica es de un paciente con amiloidosis mediada por transtiretina hereditaria (ATTR). El anticuerpo de captura es 9D5 y el anticuerpo reportero es un anticuerpo anti-TTR policlonal. Tambien se refiere a un metodo para determinar una proporcion del nivel de transtiretina (TTR) mal plegada multimerica total en relacion con el nivel de TTR mal plegada total en una muestra biologica y un metodo para determinar acoplamiento a diana in vivo de un anticuerpo de ensayo administrado a un sujeto. Dichos metodos pueden ser utilizados para diagnosticar enfermedades o trastornos asociados con acumulacion de TTR
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762569438P | 2017-10-06 | 2017-10-06 | |
US201762579817P | 2017-10-31 | 2017-10-31 | |
US201862647582P | 2018-03-23 | 2018-03-23 | |
PCT/US2018/054723 WO2019071206A1 (en) | 2017-10-06 | 2018-10-05 | METHODS OF DETECTING TRANSTHYRETIN |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210042A1 true PE20210042A1 (es) | 2021-01-08 |
Family
ID=65995330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000647A PE20210042A1 (es) | 2017-10-06 | 2018-10-05 | Metodos para detectar transtiretina |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200249244A1 (es) |
EP (1) | EP3691626A4 (es) |
JP (1) | JP7292569B2 (es) |
KR (1) | KR102581734B1 (es) |
CN (1) | CN111757730A (es) |
AU (1) | AU2018345807A1 (es) |
BR (1) | BR112020006791A2 (es) |
CA (1) | CA3077353A1 (es) |
CU (1) | CU20200022A7 (es) |
MX (1) | MX2020003043A (es) |
PE (1) | PE20210042A1 (es) |
SG (1) | SG11202002490UA (es) |
WO (1) | WO2019071206A1 (es) |
ZA (1) | ZA202002137B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2019071205A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETIN ANTIBODY |
EP3717512A4 (en) | 2017-11-29 | 2021-08-25 | Prothena Biosciences Limited | LYOPHILIZED FORMULATION OF A MONOCLONAL ANTIBODY AGAINST TRANSTHYRETINE |
US20220283185A1 (en) * | 2019-08-27 | 2022-09-08 | University Of Southern California | Assays for detecting and quantifying a biomarker of pericyte injury |
TW202333786A (zh) * | 2021-11-15 | 2023-09-01 | 英屬開曼群島商先知生物科技股份有限公司 | 逆轉treml1誘導之免疫抑制之方法 |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
WO2023192161A2 (en) * | 2022-03-28 | 2023-10-05 | Intrinsic Medicine, Inc. | Methods and compositions for attenuating immune response associated with rna therapeutics |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2078189B1 (en) * | 2006-10-20 | 2012-10-10 | Clondiag GmbH | Assay devices and methods for the detection of analytes |
US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
CN113156139A (zh) | 2013-01-03 | 2021-07-23 | 梅索磅秤技术有限公司 | 测定实验对象组 |
US9790269B2 (en) * | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
WO2015092077A1 (en) * | 2013-12-20 | 2015-06-25 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor |
JP6818268B2 (ja) * | 2014-01-29 | 2021-01-20 | Kmバイオロジクス株式会社 | 抗トランスサイレチンヒト化抗体 |
EP3981874A1 (en) * | 2014-01-29 | 2022-04-13 | KM Biologics Co., Ltd. | Anti-transthyretin human antibody |
JP6672270B2 (ja) * | 2014-08-29 | 2020-03-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | トランスサイレチン(ttr)媒介アミロイドーシスの治療方法 |
US10464999B2 (en) * | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI718122B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
US9879080B2 (en) * | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI781507B (zh) * | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2018
- 2018-10-05 BR BR112020006791-1A patent/BR112020006791A2/pt unknown
- 2018-10-05 EP EP18864376.1A patent/EP3691626A4/en active Pending
- 2018-10-05 AU AU2018345807A patent/AU2018345807A1/en active Pending
- 2018-10-05 CA CA3077353A patent/CA3077353A1/en active Pending
- 2018-10-05 US US16/753,661 patent/US20200249244A1/en active Pending
- 2018-10-05 MX MX2020003043A patent/MX2020003043A/es unknown
- 2018-10-05 SG SG11202002490UA patent/SG11202002490UA/en unknown
- 2018-10-05 CN CN201880064631.6A patent/CN111757730A/zh active Pending
- 2018-10-05 JP JP2020519805A patent/JP7292569B2/ja active Active
- 2018-10-05 KR KR1020207010132A patent/KR102581734B1/ko active IP Right Grant
- 2018-10-05 CU CU2020000022A patent/CU20200022A7/es unknown
- 2018-10-05 PE PE2020000647A patent/PE20210042A1/es unknown
- 2018-10-05 WO PCT/US2018/054723 patent/WO2019071206A1/en unknown
-
2020
- 2020-05-04 ZA ZA2020/02137A patent/ZA202002137B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20200249244A1 (en) | 2020-08-06 |
KR20200067144A (ko) | 2020-06-11 |
BR112020006791A2 (pt) | 2020-12-01 |
MX2020003043A (es) | 2020-10-05 |
CA3077353A1 (en) | 2019-04-11 |
SG11202002490UA (en) | 2020-04-29 |
JP2020537128A (ja) | 2020-12-17 |
EP3691626A1 (en) | 2020-08-12 |
EP3691626A4 (en) | 2021-06-30 |
KR102581734B1 (ko) | 2023-09-22 |
CN111757730A (zh) | 2020-10-09 |
JP7292569B2 (ja) | 2023-06-19 |
AU2018345807A1 (en) | 2020-03-12 |
WO2019071206A1 (en) | 2019-04-11 |
ZA202002137B (en) | 2023-07-26 |
CU20200022A7 (es) | 2021-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210042A1 (es) | Metodos para detectar transtiretina | |
CL2020000830A1 (es) | Molécula de unión a cd3 que comprende un dominio variable de cadena ligera (vl) y un dominio variable de cadena pesada (vh) capaz de unir un epítope de cd3 humano y de mamíferos no humanos; composición farmacéutica que comprende dicha molécula y su uso. (divisional solicitud 201303329) | |
BR112014006741A2 (pt) | método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial | |
BR112014013082A2 (pt) | método para detectar adutos nucleossomos | |
EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
JP2017524725A5 (es) | ||
CR20130621A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
TR201904638T4 (tr) | pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. | |
AR103935A1 (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 | |
AR053948A1 (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente | |
NZ601858A (en) | Methods and compositions for diagnosis and treatment of amyloidosis | |
EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
BR112012016820A2 (pt) | Metodos para tratamento de cancer de seio | |
CL2013003605A1 (es) | Metodo para la evaluacion del riesgo de un evento tromboembólico en un sujeto que comprende determinar la presencia de serpin a 10 (inhibidor de la proteina z); kit que comprende reactivos para detectar serpin a 10. | |
EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
BR112016007474A2 (pt) | diagnóstico e tratamento de síndrome do intestino irritável e doença inflamatória intestinal | |
BR112012019475A2 (pt) | "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra | |
EA202192606A1 (ru) | Антитела к пироглутамат--амилоиду и их применение | |
JP2021176869A (ja) | Vi型コラーゲン配列に関するイムノアッセイ | |
BR112017006315A2 (pt) | agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits | |
BR112014005573A2 (pt) | Anticorpo monoclonal b7-h6 terapeuticamente ativo contra polipeptídeo b7-h6 | |
AR117735A1 (es) | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO | |
WO2014169011A3 (en) | Methods for treating immune diseases | |
RU2014113841A (ru) | Способ ранней диагностики эндогенной интоксикации | |
CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto |